Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 197

1.

Allogeneic hematopoietic stem-cell transplantation for sickle cell disease.

Hsieh MM, Kang EM, Fitzhugh CD, Link MB, Bolan CD, Kurlander R, Childs RW, Rodgers GP, Powell JD, Tisdale JF.

N Engl J Med. 2009 Dec 10;361(24):2309-17. doi: 10.1056/NEJMoa0904971.

2.

Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.

Hsieh MM, Fitzhugh CD, Weitzel RP, Link ME, Coles WA, Zhao X, Rodgers GP, Powell JD, Tisdale JF.

JAMA. 2014 Jul 2;312(1):48-56. doi: 10.1001/jama.2014.7192.

3.

Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease.

Saraf SL, Oh AL, Patel PR, Jalundhwala Y, Sweiss K, Koshy M, Campbell-Lee S, Gowhari M, Hassan J, Peace D, Quigley JG, Khan I, Molokie RE, Hsu LL, Mahmud N, Levinson DJ, Pickard AS, Garcia JG, Gordeuk VR, Rondelli D.

Biol Blood Marrow Transplant. 2016 Mar;22(3):441-8. doi: 10.1016/j.bbmt.2015.08.036. Epub 2015 Sep 5.

4.

Hematopoietic stem-cell transplantation for adults with sickle cell disease.

Abboud MR.

N Engl J Med. 2009 Dec 10;361(24):2380-1. doi: 10.1056/NEJMe0908574. No abstract available.

PMID:
20007564
5.

Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.

Grosskreutz C, Ross V, Scigliano E, Fruchtman S, Isola L.

Biol Blood Marrow Transplant. 2003 Jul;9(7):453-9.

6.

In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.

Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsh JC, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH, Mackinnon S.

Blood. 2000 Oct 1;96(7):2419-25.

8.

Impact of donor age on outcome after allogeneic hematopoietic cell transplantation.

Rezvani AR, Storer BE, Guthrie KA, Schoch HG, Maloney DG, Sandmaier BM, Storb R.

Biol Blood Marrow Transplant. 2015 Jan;21(1):105-12. doi: 10.1016/j.bbmt.2014.09.021. Epub 2014 Sep 30.

9.

Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia.

Iannone R, Casella JF, Fuchs EJ, Chen AR, Jones RJ, Woolfrey A, Amylon M, Sullivan KM, Storb RF, Walters MC.

Biol Blood Marrow Transplant. 2003 Aug;9(8):519-28.

10.

Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft.

Horwitz ME, Barrett AJ, Brown MR, Carter CS, Childs R, Gallin JI, Holland SM, Linton GF, Miller JA, Leitman SF, Read EJ, Malech HL.

N Engl J Med. 2001 Mar 22;344(12):881-8.

11.

Partially mismatched pediatric transplants with allogeneic CD34(+) blood cells from a related donor.

Kawano Y, Takaue Y, Watanabe A, Takeda O, Arai K, Itoh E, Ohno Y, Teshima T, Harada M, Watanabe T, Okamoto Y, Abe T, Kajiume T, Matsushita T, Ikeda K, Endo M, Kuroda Y, Asano S, Tanosaki R, Yamaguchi K, Law P, McMannis JD.

Blood. 1998 Nov 1;92(9):3123-30.

12.

Clinical evaluation of busulfan, cladribine and alemtuzumab as reduced intensity conditioning for stem cell transplantation.

Halaburda K, Marianska B, Warzocha K, Nasilowska-Adamska B, Szczepinski A, Tomaszewska A, Sawecka J, Skulimowska J.

Ann Transplant. 2009 Apr-Jun;14(2):7-12.

13.
14.
15.

Allogeneic hematopoietic stem-cell transplantation, mixed chimerism, and tolerance in living related donor renal allograft recipients.

Trivedi HL, Vanikar AV, Modi PR, Shah VR, Vakil JM, Trivedi VB, Khemchandani SI.

Transplant Proc. 2005 Mar;37(2):737-42.

PMID:
15848518
17.

Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.

Strober S.

Blood Cells Mol Dis. 2008 Jan-Feb;40(1):48-54. Epub 2007 Sep 10. Review.

PMID:
17827036
18.

Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells.

Cieri N, Greco R, Crucitti L, Morelli M, Giglio F, Levati G, Assanelli A, Carrabba MG, Bellio L, Milani R, Lorentino F, Stanghellini MT, De Freitas T, Marktel S, Bernardi M, Corti C, Vago L, Bonini C, Ciceri F, Peccatori J.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1506-14. doi: 10.1016/j.bbmt.2015.04.025. Epub 2015 May 19.

19.

In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.

Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsh JC, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, Ruiz de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH, MacKinnon S.

Cytotherapy. 2001;3(3):197-201.

PMID:
12171726
20.

Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab.

Das-Gupta EP, Russell NH, Shaw BE, Pearce RM, Byrne JL.

Biol Blood Marrow Transplant. 2007 Jun;13(6):724-33.

Supplemental Content

Support Center